Skip to content

Deep multimodal clustering identifies biological subtypes of normal aging with divergent cognitive decline risk

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

The study reveals marked variability among individuals who are otherwise all defined as cognitively normal, and provides a data-driven stratification framework for enriching disease-modifying and preventive trials by identifying cognitively normal individuals at high risk for future cognitive decline.

View source

Similar papers

Preprint Aug 2026

Multimodal risk trajectories reveal heterogeneous paths to dementia

NetMoint is developed, a multimodal framework integrating partially observed plasma proteomic, structural magnetic resonance imaging and cerebral haemodynamic phenotypes to predict individualized risks of Alzheimer's disease, vascular dementia and frontotemporal dementia across 1, 5, 10- and 20-year horizons, establish...

Zhi-Qi Lee, Hao-Wen Li, Tao Liu et al. · 0 citations
Open access Sep 2026

Data-driven subtypes of Alzheimer’s Disease: A multicohort study

These findings, replicated in four diverse and independent datasets, support imaging-based subtyping as a scalable and clinically translatable approach for capturing heterogeneity in AD pathophysiology and associated cognitive trajectories.

A. Metz, Cassandra Polizzi, R. Moqadam et al. · 0 citations
Open access Sep 2026

Spatiotemporal Atrophy Subtypes in Alzheimer's Disease: Neurodegenerative-Vascular Associations and Potential Prognostic Value.

Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.

Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al. · 0 citations
Open access Aug 2026

Multivariate blood biomarkers capture resilience and resistance phenotypes across the Alzheimers disease spectrum

A multivariate blood-based framework integrating 19 molecular assays and six risk instruments in the Bio-Hermes-001 cohort supports resilience and resistance as molecularly distinct subgroups and provides a scalable framework for pathology-informed stratification and mechanistic investigation.

K. Mavromati, C. Dalby, A. Dibble et al. · 0 citations
Review Open access Sep 2026

The path to treating multiple-etiology dementia: Combining vascular risk control and disease-modifying neurodegenerative therapies

An integrated research roadmap for MED is proposed that prioritizes biomarker-enriched cohorts, combination vascular and neurodegenerative therapies, and pragmatic trials, and offers the most plausible strategy to reduce the growing global burden of MED.

Adam de Havenon, Kevin N. Sheth, Carolyn A. Fredericks et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.